drugset / Trial / NCT01155713

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

NCT01155713

Phase 1 Completed 63 enrolled Novartis Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor.

Timeline

Start
2010-07
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule Oral

Indications